Dashboard
1
High Management Efficiency with a high ROE of 21.94%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 42.92
3
Poor long term growth as Operating profit has grown by an annual rate 20.17% of over the last 5 years
4
Positive results in Dec 24
5
With ROE of 23.09%, it has a Fair valuation with a 2.65 Price to Book Value
6
Consistent Returns over the last 3 years
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.95%
0%
-6.95%
6 Months
32.3%
0%
32.3%
1 Year
87.52%
0%
87.52%
2 Years
215.04%
0%
215.04%
3 Years
275.51%
0%
275.51%
4 Years
301.89%
0%
301.89%
5 Years
375.08%
0%
375.08%
Consun Pharmaceutical Group Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
15.43%
EBIT Growth (5y)
20.17%
EBIT to Interest (avg)
42.92
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.88
Sales to Capital Employed (avg)
0.66
Tax Ratio
10.07%
Dividend Payout Ratio
49.91%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
121.96%
ROE (avg)
21.94%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
2.65
EV to EBIT
7.41
EV to EBITDA
7.03
EV to Capital Employed
13.91
EV to Sales
2.41
PEG Ratio
0.69
Dividend Yield
NA
ROCE (Latest)
187.86%
ROE (Latest)
23.09%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
2,862.10
2,720.70
5.20%
Operating Profit (PBDIT) excl Other Income
932.70
903.30
3.25%
Interest
23.50
12.70
85.04%
Exceptional Items
0.00
0.00
Consolidate Net Profit
869.10
795.10
9.31%
Operating Profit Margin (Excl OI)
295.90%
299.60%
-0.37%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 5.20% vs 10.41% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 9.31% vs 12.37% in Dec 2022
About Consun Pharmaceutical Group Ltd. 
Consun Pharmaceutical Group Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






